What is the future for therapies derived from the microbiome (pharmabiotics)?

G.T. Rijkers, L. Mulder, F.M. Rombouts, L.M.A. Akkermans

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The personal gut microbiota is characterized by species composition, enterotype, and bacterial gene counts. Gut microbiota can be viewed as a complex microecosystem. Regulation of the diversity and stability of the gut microbiota is therefore critical for the development of future therapies. The areas with high potential for personalized management of gut microbiota are obesity and the metabolic syndrome, prevention and control of (recurrent) infections, immune-mediated disorders, and the gut-brain axis. A true and deeper understanding of the interaction between the microbiota and the host, as well as a better matching of probiotic and prebiotic mechanisms with clinical indications will be required for successful future implementation of these therapies.
Original languageEnglish
Title of host publicationProbiotic bacteria and their effect on human health and well-being
EditorsA. Guarino, E.M.M. Quigley, W.A. Walker
Place of PublicationBasel
Pages186-196
Number of pages202
DOIs
Publication statusPublished - 2013

Publication series

NameWorld Review of Nutrition and Dietetics
PublisherKarger
Number107

Fingerprint Dive into the research topics of 'What is the future for therapies derived from the microbiome (pharmabiotics)?'. Together they form a unique fingerprint.

Cite this